Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mirum PharmaceuticalsMIRM -0.25%50 Debt-to-Equity is 1.34 as of Mar. 2026, which is 4367% above its 10-year median of 0.03. GuruFocus rates MIRM with a GF Score™ of 50/100 and a GF Value™ of $83.28 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 970 Biotechnology companies, Mirum Pharmaceuticals ranks worse than 90.31% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Mirum Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
MIRM'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.08 Med: 0.03 Max: 3.92
Current: 1.34
During the past 8 years, the highest Debt-to-Equity Ratio of Mirum Pharmaceuticals was 3.92. The lowest was -0.08. And the median was 0.03.
MIRM's Debt-to-Equity is ranked worse than 90.31% of 970
companies
in the Biotechnology industry
Industry Median: 0.16
vs MIRM: 1.34
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Mirum Pharmaceuticals Debt-to-Equity Related Terms
Mirum Pharmaceuticals Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Mirum Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIRM vs COGT, RYTM, ERAS: Debt-to-Equity Comparison
For the Biotechnology subindustry, Mirum Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mirum Pharmaceuticals Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Mirum Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mirum Pharmaceuticals (MIRM) has a Debt-to-Equity of 1.34 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Mirum Pharmaceuticals and its competitors. This is 4367% above median its historical median of 0.03. According to the industry distribution chart, Mirum Pharmaceuticals ranks #876 out of 970 companies in the Biotechnology industry, placing it in the top 90.3%.
Is Mirum Pharmaceuticals' Debt-to-Equity too high?
Mirum Pharmaceuticals' current Debt-to-Equity of 1.34 is 4367% above median its 10-year median of 0.03. The Biotechnology industry median Debt-to-Equity is 0.16. Mirum Pharmaceuticals' value of 1.34 is 737.5% above this industry median. Based on the distribution chart, Mirum Pharmaceuticals ranks #876 out of 970 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Mirum Pharmaceuticals has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Debt-to-Equity compare to COGT and RYTM?
According to the Biotechnology industry distribution chart, Mirum Pharmaceuticals ranks #876 out of 970 companies for Debt-to-Equity. This places Mirum Pharmaceuticals in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Mirum Pharmaceuticals' value of 1.34 is 737.5% above this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 0.16, Mirum Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 970 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mirum Pharmaceuticals's current Debt-to-Equity of 1.34 is 737.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Mirum Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mirum Pharmaceuticals's current Debt-to-Equity is 1.34, which is 4367% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Mirum Pharmaceuticals (MIRM) is currently considered Modestly Overvalued. The stock's GF Value™ is $83.28, compared to a current price of $104.33 — trading 25.3% above its estimated fair value. The current Debt-to-Equity is 1.34, which is 4367% above median its 10-year median of 0.03 and 737.5% above the Biotechnology industry median of 0.16. Mirum Pharmaceuticals' overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Mirum Pharmaceuticals (MIRM), the current Debt-to-Equity is 1.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mirum Pharmaceuticals (MIRM) Overvalued in 2026?
Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued.
The current stock price of $104.33 is trading 25.3% above its estimated GF Value™ of $83.28.
GuruFocus considers Mirum Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for MIRM:
Debt-to-Equity: 1.34 (4367% above median its 10-year median of 0.03)
GF Value™: $83.28 vs. price of $104.33 (25.3% above fair value)
Industry Position: 737.5% above the Biotechnology median (#876 of 970)
No single metric tells the full story. See the MIRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
50GF Score
Get the complete analysis for MIRM
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIRM has been successfully added to your 
